Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Benitec Biopharma Inc. (BNTC)

Benitec says FDA requested more data for BB-301 pivotal study; start still mid-2027

Mixed Impact 3 of 5 legal/regulatory Written later

Benitec Biopharma said the FDA asked for additional available data, including from the company-sponsored OPMD Natural History Study, as discussions on an open-label, single-arm pivotal study for BB-301 continue. The company said it expects to confirm the final pivotal design in the first quarter of 2027 and that the pivotal study timeline remains on track, with patient enrollment planned to begin in mid-2027.

Key points

  • FDA requested additional available data, including from the Benitec-sponsored OPMD Natural History Study
  • Final pivotal study design expected to be confirmed in 1Q 2027
  • Patient enrollment for the BB-301 pivotal study planned to begin in mid-2027
  • Interim BB-301 Phase 1b/2a results to be presented as a late-breaking poster at ESGCT in Hamburg, October 27-30, 2026

The filing

CompanyBenitec Biopharma Inc. (BNTC)
Form8-K, current report
Filed with the SECOct 5, 2026, 8:08 AM ET
Accession number0001193125-26-413177

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.